

Registration no:

--	--	--	--	--	--	--	--	--	--

Total Number of Pages: 02

**B.PHARM**  
**PH.8.1****8<sup>th</sup> Semester Regular / Back Examination 2015-16****Pharmaceutics – VII****(PHARMACEUTICAL TECHNOLOGY-III)****BRANCH(S): Pharmacy****Time: 3 Hours****Max Marks: 70****Q.CODE: W124**

**Answer Question No.1 which is compulsory and any five from the rest.**  
**The figures in the right hand margin indicate marks.**

**Q1** Answer the following questions: **(2 x 10)**

- a) Mention the significance of Carr's Index in preformulation study.
- b) Describe correlation between particle size and dissolution of a drug.
- c) What is enteric coating? Give the name of two polymers used for enteric coating tablets.
- d) Give the schematic representation of rate limiting steps in the design of controlled release drug delivery systems.
- e) What is liposome? Mention the potential advantage of liposome for parenteral therapy.
- f) Write very briefly about magnetic microspheres.
- g) Write main points of bioavailability testing protocol.
- h) Mention very briefly the general characteristics of lipstick.
- i) Describe the process of evaluation of Shampoo.
- j) What is dose dumping, describe with proper reason.

**Q2** What is preformulation? Mention the objectives and timing and protocol of preformulation study. **(2+3+5)**

- Q3**
- a) Explain briefly the factors influencing the development of a controlled released dosage form. **(7)**
  - b) Describe how controlled released and conventional dosage forms are differentiated. **(3)**

**Q4** Describe briefly about (any two) **(5 x 2)**

- a) Partition Coefficient
- b) Intrinsic solubility
- c) Polymorphism

**Q5** Describe the design and production of diffusion controlled drug delivery system. **(10)**

**Q6** a) Write the rationality to design the transdermal drug delivery systems. **(4)**  
b) Describe different types of TDDS. **(6)**

**Q7** Write notes on (any two) **(5 x 2)**  
a) Resealed erythrocytes  
b) IUD  
c) Deodorants

**Q8** Describe the USP apparatus I used in dissolution study, how it differ from apparatus II. **(10)**